Physician profile
Rodney E Hillis
NPI 1336138494
$16,669.54
in general payments reported to CMS, 2019-2025
49 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,065 · 2020: $1,877 · 2021: $3,174 · 2022: $2,774 · 2023: $2,310 · 2024: $2,390 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,772 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,771.92 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,999.56 | 2021-2025 | |
| Ucb, INC. | $1,608.65 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,313.74 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $899.16 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $894.70 | 2019-2025 | Reyvow, Emgality, Amyvid |
| Pfizer INC. | $862.23 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $854.39 | 2019-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $846.11 | 2019-2022 | |
| Eisai INC. | $623.24 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $564.81 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $550.28 | 2019-2022 | |
| Biogen, INC. | $533.21 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Amgen INC. | $496.52 | 2019-2024 | Uplizna |
| Novartis Pharmaceuticals Corporation | $487.84 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $397.36 | 2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $345.75 | 2020-2023 | Nourianz |
| Alexion Pharmaceuticals, INC. | $290.31 | 2019-2025 | Ultomiris |
| Biohaven Pharmaceuticals, INC. | $222.49 | 2021 | |
| Lundbeck LLC | $212.78 | 2022-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $203.19 | 2021-2025 | Crexont, Rytary |
| Astrazeneca Pharmaceuticals Lp | $202.60 | 2021-2022 | |
| Ge Healthcare | $199.66 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $185.60 | 2023-2025 | Nuedexta, Rexulti |
| Allergan, INC. | $184.00 | 2020 | |
| Acorda Therapeutics, INC | $160.19 | 2019-2021 | |
| Celgene Corporation | $155.17 | 2023-2025 | Zeposia |
| Upsher-Smith Laboratories LLC | $152.30 | 2019-2022 | |
| Aucta Pharmaceuticals, INC. | $124.56 | 2025 | Motpoly Xr |
| Emd Serono, INC. | $118.02 | 2019 | |
| Sumitomo Pharma America, INC. | $115.98 | 2023 | Aptiom |
| Avanir Pharmaceuticals, INC. | $94.00 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $88.96 | 2022-2025 | Keveyis, Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $79.99 | 2022 | |
| Genentech USA, INC. | $79.29 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Csl Behring | $72.31 | 2019-2023 | Hizentra |
| Neurocrine Biosciences, INC. | $69.17 | 2020-2025 | |
| Grifols USA, LLC | $56.35 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $55.08 | 2022 | |
| Genzyme Corporation | $46.40 | 2023 | |
| Zyla Life Sciences, INC. | $34.44 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $31.55 | 2022 | |
| Neurelis, INC. | $28.74 | 2025 | Valtoco |
| Promius Pharma LLC | $25.19 | 2019 | |
| Argenx US, INC. | $23.49 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Mdd US Operations, LLC | $21.21 | 2022 | |
| Abbott Laboratories | $17.70 | 2024 | Amplatzer Talisman |
| Dynasplint Systems INC. | $16.56 | 2025 | Dynasplint |
| Tanabe Pharma America, INC. | $12.48 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Hillis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.